Succeeds Dr. Stephen Schwartz Following
14-Year Tenure
BURLINGTON, Mass., Sept. 4,
2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA)
("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as
President and CEO effective September 9,
2024, succeeding Dr. Stephen
Schwartz, who is retiring following a distinguished tenure.
Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth
and successful transition.
Mr. Marotta has two decades of experience leading global
companies in life sciences, medical devices, and diagnostics, and
is joining Azenta from Patient Square Capital, a leading healthcare
investment firm, where he serves as Executive in Residence.
Previously, he served as CEO and President of PHC Holdings
Corporation (formerly Panasonic Health Care), a diversified global
life sciences, diagnostics, and medical device company focused on
precision healthcare, growing global revenues and leading its IPO
from owners KKR & Co. He also held a variety of senior
executive roles in leading life sciences companies, including at
Danaher Corporation, Envista Holdings Corporation, and Cardinal
Health, Inc., where he demonstrated consistent achievement in
organic revenue growth, operational efficiencies, and significant
value-creating transactions. Mr. Marotta began his career in sales
leadership roles for therapeutics and medical device offerings.
Frank E. Casal, Chairman of the
Azenta Board said, "Following a rigorous search process, aided by a
leading executive search firm, the Board and I are thrilled to
welcome John as our next President and CEO. We are confident he is
the ideal person to lead Azenta into our next chapter. John brings
extensive experience leading complex high-growth life sciences
businesses around the globe. We look forward to working with him to
amplify Azenta's momentum and deliver sustainable value for
shareholders."
Mr. Marotta said, "I am excited to join Azenta and get to know
its talented teams worldwide. I have been impressed by Azenta's
evolution and am confident that, together, we will expand on its
strong foundation to further enhance its offerings while driving
growth and profitability. I look forward to hitting the ground
running and executing on our tremendous opportunities ahead."
Mr. Casal continued, "The Board and I extend our deepest
gratitude to Steve for his leadership over the last 14 years. Steve
joined as President of Brooks Automation in April 2010 and was appointed CEO in August 2010. He led the creation of Azenta as a
business division of Brooks into the standalone, pure-play
life-sciences leader that it is today, and oversaw the sale of the
Semiconductor Solutions Group. Steve leaves a profound impression
on all stakeholders, having led our team to create significant
value for shareholders during his tenure and enable customers to
realize impactful breakthroughs. We thank Steve and wish him all
the best."
Dr. Schwartz added, "It has been a privilege to be a part of
this amazing Azenta team on a journey to become an established
life-sciences company that we believe uniquely enables customers
around the globe in their pursuit of scientific progress. I am
confident in Azenta's future success as it moves into this next
chapter and I look forward to working with John through the
transition."
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life
sciences solutions worldwide, enabling impactful breakthroughs and
therapies to market faster. Azenta provides a full suite of
reliable cold-chain sample management solutions and multiomics
services across areas such as drug development, clinical research
and advanced cell therapies for the industry's top pharmaceutical,
biotech, academic and healthcare institutions globally. Our global
team delivers and supports these products and services through our
industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude,
Limfinity, Freezer Pro, Barkey, and B Medical Systems.
Azenta is headquartered in Burlington, Massachusetts, with operations in North
America, Europe, and Asia. For more information, please
visit www.azenta.com.
"Safe Harbor Statement" under Section 21E of the Securities
Exchange Act of 1934
Some statements in this release are forward-looking statements
made under Section 21E of the Securities Exchange Act of 1934.
These statements are neither promises nor guarantees but involve
risks and uncertainties, both known and unknown, that could cause
Azenta's financial and business results to differ materially from
our expectations. They are based on the facts known to management
at the time they are made. Forward-looking statements include but
are not limited to statements about the transition to John P. Marotta as Azenta's President and CEO
and ability to deliver shareholder value. Factors that could cause
results to differ from our expectations include the following: our
ability to ensure a smooth CEO transition; our ability to reduce
costs effectively; the volatility of the life sciences markets the
Company serves; our possible inability to meet demand for our
products due to difficulties in obtaining components and materials
from our suppliers in required quantities and of required quality;
the inability of customers to make payments to us when due; price
competition; disputes concerning intellectual property;
uncertainties in global political and economic conditions; and
other factors and other risks, including those that we have
described in our filings with the Securities and Exchange
Commission, including but not limited to our Annual Report on Form
10-K, Current Reports on Form 8-K and our Quarterly Reports on Form
10-Q. As a result, we can provide no assurance that our future
results will not be materially different from those projected.
Azenta expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statement to reflect
any change in our expectations or any change in events, conditions,
or circumstances on which any such statement is based. Azenta
undertakes no obligation to update the information contained in
this press release.
AZENTA INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis and Investor
Relations
ir@azenta.com
Sherry Dinsmore
sherry.dinsmore@azenta.com
AZENTA MEDIA CONTACT:
Emily
Claffey
FGS Global
Azenta@FGSGlobal.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/azenta-announces-appointment-of-john-p-marotta-as-ceo-302237689.html
SOURCE Azenta
